South West Myeloma Group
14 October 2020
Ceri Bygrave is a graduate of UWCM Cardiff and did her junior doctor training in South Wales and Australia. She then progressed as a haematology SpR in the Wales deanery which included 2 years research looking at the microenvironment in AML, supervised by Professor Alan Burnett and culminating in an MPhil. Myeloma has been her interest since undergraduate days and she was appointed as Myeloma Lead in UHW Cardiff in October 2014 and has helped set up the service and develop the clinical and research aspects of the department. She is also a member of the UKMRA and the MUK CTN.
Dr Hunter graduated from Bristol Universty in 1994 and completed post-graduate training in general medicine and then haematology in the South West. She also completed two years laboratory research in acute leukaemia in Nottingham. Her particular areas of expertise are stem cell transplantation, acute leukaemia and multiple myeloma. She is involved in actively recruiting to clinical trials in these specialities.
Dr Parkins has been a Consultant Haematologist at Royal Cornwall Hospital since 2007. Prior to that she trained in haematology in Leeds and the South West She spent 15 months in Ghana researching lymphoproliferative disorders there for an MD thesis as well as working as a haematologist and teaching medical students. Her subspecialisation is myeloma.
Professor Kwee Yong
Kwee Yong is Professor of Haematology at University College London. She was educated at Oxford and University College London. She completed her PhD in haemopoietic growth factors, and returned to UCL as Senior Lecturer in 1999. She leads the multiple myeloma programme at UCL. She is an executive member of the UK Myeloma Research Alliance, a member of the National Cancer Research Institute Haematology-Oncology Clinical Studies Group, and past chair of the UK Myeloma Forum Executive committee. She is CI on several National Cancer Research Network trials in myeloma, employing novel risk stratified strategies, and immunotherapy. Professor Yong runs a laboratory programme working on aspects of myeloma biology, immune environment and translational strategies including CAR-T therapies. A particular focus is the contribution of immune dysfunction to clinical outcomes including progression from precursor disease. The programme receives funding from the Medical Research Council, Cancer Research UK and Blood Cancer UK. Professor Yong has published over 150 original papers in peer-reviewed journals, and is a reviewer for international journals and grant-awarding bodies.